Bronchogen is one of the organ-specific short peptides from Professor Vladimir Khavinson’s bioregulator programme. It is a four-amino-acid chain, Ala-Glu-Asp-Leu (AEDL), sold for the bronchial lining and lungs, and it turns up in long-COVID and “lung longevity” stacks.
My one-line verdict: interesting rat data, a plausible story, and no human evidence at all. Most of what is written about Bronchogen online goes far beyond what the studies show.
For the background on the whole class, start with the peptide bioregulators overview.
At a Glance
| Property | Detail |
|---|---|
| Sequence | Ala-Glu-Asp-Leu (AEDL), synthetic tetrapeptide |
| Origin | St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group) |
| Proposed mechanism | Enters cells and binds DNA/chromatin, changing gene expression in bronchial epithelium (developer hypothesis) |
| Marketed for | Bronchial and lung support, COPD, post-infectious airway recovery |
| Route | Subcutaneous injection (research vials); the oral lung products in the same family are Chonluten (Cytogen) and Taxorest (Cytomax) |
| Typical dose range | 1–2 mg SC daily for 10–20 days (practice protocols) |
| Evidence level | Limited: rat and cell studies only, from groups linked to the developers |
| Regulatory status | Not FDA- or EMA-approved; sold as a research chemical; not named by WADA, falls under S0 (non-approved substances) |
How it works
The Khavinson group’s theory is that very short peptides cross cell and nuclear membranes and bind specific DNA sequences, switching tissue-specific genes back on in aging cells. For Bronchogen, the group has modelled binding to a “ctcc” DNA motif [1], measured a small rise in DNA melting temperature in the test tube [2], and reported that it stimulated differentiation markers (CXCL12, Hoxa3) in aging human bronchial epithelial cell cultures [3]. A 2023 modelling paper argued that AEDL is small enough to be carried into cells by the peptide transporter PEPT1 and the amino-acid transporters LAT1/LAT2 [4].
All of this is computational or test-tube work. It describes a possible mechanism; it does not show that injected Bronchogen reaches the airways in people or changes how they breathe.
What the evidence shows
Human studies
None. I found no PubMed-indexed human trial, case series or pharmacokinetic study of Bronchogen.
Animal and cell studies
| Study | Model | Finding |
|---|---|---|
| Kuzubova et al. 2015 [5] | Rats, COPD induced by 60 days of intermittent NO2 exposure | One month of Bronchogen reduced goblet-cell hyperplasia, squamous metaplasia and lymphocytic infiltration in the bronchi |
| Titova et al. 2017 [6] | Same rat model | Less neutrophilic inflammation and a more normal cytokine profile in lavage fluid |
| Khavinson et al. 2012 [3] | Aging human bronchial epithelial cell cultures | Bronchogen raised differentiation markers that fall with passage number |
| Zakutskii et al. 2006 [7] | Lung tissue explants from young and old rats | Stimulated explant growth at 0.05 ng/ml |
The rat studies are the most relevant data, and they come from a pulmonology group working with the Khavinson programme. They have not been replicated independently, and NO2-exposed rats are a rough model of human COPD.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
There is no dose-finding study in humans. The numbers below come from the products themselves and from practitioner and community protocols.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Lung “maintenance” course | 1–2 mg | SC injection | Once daily | 10–20 days (one 20 mg vial per course), 1–3 courses a year | Practice protocol (r/peptidebioregulators, r/PeptideGuide) |
| Low-dose variant | 100–500 µg | SC injection | Once daily | 10–30 days | Practice protocol (vendor protocol pages such as MyPeptideMatch for sister peptides; ZyraTrack forum) |
| High-dose variant | 5–10 mg | SC injection | Once daily | 10–20 days | Practice protocol, vendor sites only (Pepdex, Peptide-DB); no trial basis |
| Oral alternative (Chonluten, Cytogen capsules) | 1–2 capsules | Oral, with meals | Twice daily | 30 days, repeat after 3–6 months | Label (supplement directions, ipept.eu) |
| Long-COVID airway stack | Bronchogen 1 mg + Chonluten 1 mg | SC injection | Once daily | Course length not stated | Anecdotal (r/PeptideGuide) |
Notice the spread: published practice protocols differ by a factor of 50 or more for the same vial. That alone tells you nobody has established a dose. For reconstitution and injection technique, see the peptide injection guide.
What people report: what works and what doesn’t
Reports about Bronchogen specifically are sparse; most discussion lumps it together with Chonluten.
Reported to work
- Users running Bronchogen and Chonluten together at about 1 mg a day each describe subjectively easier breathing during long-COVID recovery (r/PeptideGuide).
- Similar reports exist for the lung peptide Chonluten alone in asthma, with less reliance on a rescue inhaler after several weeks (r/Biohackers). These are second-hand stories without lung-function measurements.
Mixed or unclear
- Whether oral lung capsules do anything is debated; one camp argues di- and tripeptides survive digestion, others doubt it (r/NooTopics).
Reported not to work / disappointing
- In broader bioregulator threads many users say they felt nothing from organ-specific courses and question the cost (Steroidsgrabber forum). Side effects are rarely described beyond injection-site irritation.
A proper trial would need to show better spirometry (FEV1) or fewer COPD exacerbations than placebo, not just a chest that feels better.
Safety and side effects
- No human safety data. Absence of reported harm in rats is not evidence of safety in people.
- Do not replace inhalers or COPD treatment. Bronchodilators, inhaled steroids, pulmonary rehabilitation and smoking cessation have strong evidence; Bronchogen has none in humans.
- Product quality. Research vials are unregulated; content, purity and sterility vary. Short peptides attract moisture, so labelled milligrams can include water weight (Longecity discussion).
- Pregnancy, active cancer: no data; avoid.
Legal and regulatory status
- US: not FDA-approved. “Research use only” products are not approved or tested for human use.
- EU / Germany: not authorised as a medicine by the EMA or BfArM.
- Sport: not named on the WADA 2026 Prohibited List; as a substance without approval for human use it falls under S0.
How it fits
Bronchogen follows the same organ-bioregulator logic as Epithalon for the pineal gland, but with even less data. If immune recovery after infection is the real goal, Thymosin Alpha-1 at least has randomised human trials.
Related Articles
- Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows
- Thymosin Alpha-1: The Immune Modulator with Real Data
- Post-COVID Brain Fog
- How to Inject Peptides: A Step-by-Step Guide
- Peptide Safety: What You Need to Know
Frequently asked questions
What is Bronchogen?
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL) developed in Vladimir Khavinson's bioregulator programme in St. Petersburg and marketed for the bronchial lining and lungs.
Does Bronchogen work for COPD or asthma?
There are no human trials. Two rat studies in a nitrogen-dioxide model of COPD reported less airway remodelling and inflammation after a month of Bronchogen, but these results have not been tested in patients.
What is the difference between Bronchogen and Chonluten?
Both are sold as lung bioregulators. Bronchogen is the tetrapeptide AEDL, usually sold as an injectable research vial. Chonluten is the tripeptide Glu-Asp-Gly, sold as Cytogen capsules. Neither has published human trials.
What dose of Bronchogen do people use?
Commonly reported injectable protocols are 1–2 mg subcutaneously once daily for 10–20 days, repeated one to three times a year. These numbers come from practice and vendor protocols, not from trials.
Is Bronchogen legal?
It is not approved as a medicine by the FDA, the EMA or Germany's BfArM. It is sold as a research chemical, which means it has not been tested or approved for human use.
References
- Khavinson VK, Lin’kova NS, Tarnovskaya SI, et al. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016. https://pubmed.ncbi.nlm.nih.gov/27909961/
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011. https://pubmed.ncbi.nlm.nih.gov/21240358/
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22808515/
- Khavinson VK, Linkova NS, Rudskoy AI, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023. https://pubmed.ncbi.nlm.nih.gov/36979488/
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015. https://pubmed.ncbi.nlm.nih.gov/26468022/
- Titova ON, Kuzubova NA, Lebedeva ES, et al. Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology (in Russian). Ross Fiziol Zh Im I M Sechenova. 2017. https://pubmed.ncbi.nlm.nih.gov/30199201/
- Zakutskii AN, Chalisova NI, Ryzhak GA, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats (in Russian). Adv Gerontol. 2006. https://pubmed.ncbi.nlm.nih.gov/17152728/
Disclaimer: This article is for informational and educational purposes only and is not a prescription or individual medical advice. Bronchogen is not approved by the FDA or the EMA.
